PHARMAMAR HA ACTUALIZADO FASE III LAGOON LURBINECTEDIN Y SE RETRASA SU CONCLUSIÓN HASTA ABRIL 2026. : Sylentis ( Grupo Zeltia ) consigue la Patente Mundial para un Tratamiento de condiciones patológicas del sistema nervioso central .

04 octubre 2007

Sylentis ( Grupo Zeltia ) consigue la Patente Mundial para un Tratamiento de condiciones patológicas del sistema nervioso central .

TREATMENT OF CNS CONDITIONS

Publication number: WO2007107789
Publication date: 2007-09-27
Inventor: JIMENEZ ANTON ANA ISABEL (ES); SESTO YAGUE ANGELA (ES); JIMENEZ GOMEZ MA CONCEPCION (ES); GOMEZ-ACEBO GULLON EDUARDO (ES)
Applicant: SYLENTIS S A (ES); WILLIAMS GARETH OWEN (GB); JIMENEZ ANTON ANA ISABEL (ES); SESTO YAGUE ANGELA (ES); JIMENEZ GOMEZ MA CONCEPCION (ES); GOMEZ-ACEBO GULLON EDUARDO (ES)
Classification:
- international:
- European:
Application number: WO2007GB50128 20070316
Priority number(s): GB20060005337 20060317

Abstract of WO2007107789

Methods and compositions for the treatment of pathologic conditions of the central nervous system (CNS) by means of intranasal administration of a composition that modulates, by means of RNA interference, the expression and/or activity of genes involved in above-mentioned conditions.